The FDA on July 30, 2018 approved AZEDRA® for adult and pediatric patients (12 years and older) with Iobenguane scan-positive, unresectable, locally advanced or metastatic Pheochromocytoma or Paraganglioma (PPGL) who require systemic anticancer therapy. AZEDRA® is a product of Progenics Pharmaceuticals, Inc.
Top Ad
Advertisement